Zhehao Dai, Peng Xie, Xiangzhi Bai, Tang Liu, Xiaoning Guo, Lei Kuang, Ping Mu, Fangjin Lu
{"title":"Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU+ Endothelial Cells as Key Players in Tumor Progression","authors":"Zhehao Dai, Peng Xie, Xiangzhi Bai, Tang Liu, Xiaoning Guo, Lei Kuang, Ping Mu, Fangjin Lu","doi":"10.1111/cas.70138","DOIUrl":null,"url":null,"abstract":"<p>Osteosarcoma is a common malignant bone tumor in children and adolescents, characterized by high heterogeneity and poor prognosis. The role of intratumoral heterogeneity (ITH) in osteosarcoma progression remains poorly understood. To explore this, we collected paired tumor tissue samples from the central region (CR) and peripheral region (PR) of six osteosarcoma patients and performed single-cell RNA sequencing. Our findings reveal significant microenvironmental differences between these regions. The CR harbors a higher proportion of tumor cells, while the PR contains a higher proportion of endothelial cells, particularly the CLU+ subcluster. Functionally, the CR hosts a higher proportion of immune-activated myeloid cells and tumor-infiltrating lymphocytes (TILs), whereas the tumor cells in the PR show increased activation of hypoxia-related pathways. In the PR, CLU+ endothelial cells (CLU+_ECs) promote tumor metastasis by interacting with tumor cells through various ligands, including collagen family members, via ITGB1. Furthermore, CLU+_ECs induce CD8+ T cell exhaustion via the Nectin2-TIGIT pathway, suppressing the anti-tumor immune response. Overall, our study highlights the substantial spatial heterogeneity in osteosarcoma and identifies CLU+_ECs in the peripheral region as promising therapeutic targets.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 9","pages":"2568-2579"},"PeriodicalIF":4.3000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70138","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.70138","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Osteosarcoma is a common malignant bone tumor in children and adolescents, characterized by high heterogeneity and poor prognosis. The role of intratumoral heterogeneity (ITH) in osteosarcoma progression remains poorly understood. To explore this, we collected paired tumor tissue samples from the central region (CR) and peripheral region (PR) of six osteosarcoma patients and performed single-cell RNA sequencing. Our findings reveal significant microenvironmental differences between these regions. The CR harbors a higher proportion of tumor cells, while the PR contains a higher proportion of endothelial cells, particularly the CLU+ subcluster. Functionally, the CR hosts a higher proportion of immune-activated myeloid cells and tumor-infiltrating lymphocytes (TILs), whereas the tumor cells in the PR show increased activation of hypoxia-related pathways. In the PR, CLU+ endothelial cells (CLU+_ECs) promote tumor metastasis by interacting with tumor cells through various ligands, including collagen family members, via ITGB1. Furthermore, CLU+_ECs induce CD8+ T cell exhaustion via the Nectin2-TIGIT pathway, suppressing the anti-tumor immune response. Overall, our study highlights the substantial spatial heterogeneity in osteosarcoma and identifies CLU+_ECs in the peripheral region as promising therapeutic targets.
期刊介绍:
Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.
Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.